SG11202011041YA - Combination compositions comprising bisfluoroalkyl-1,4- benzodiazepinone compounds and methods of use thereof - Google Patents

Combination compositions comprising bisfluoroalkyl-1,4- benzodiazepinone compounds and methods of use thereof

Info

Publication number
SG11202011041YA
SG11202011041YA SG11202011041YA SG11202011041YA SG11202011041YA SG 11202011041Y A SG11202011041Y A SG 11202011041YA SG 11202011041Y A SG11202011041Y A SG 11202011041YA SG 11202011041Y A SG11202011041Y A SG 11202011041YA SG 11202011041Y A SG11202011041Y A SG 11202011041YA
Authority
SG
Singapore
Prior art keywords
cancer
composition
formula
another embodiment
compound
Prior art date
Application number
SG11202011041YA
Other languages
English (en)
Inventor
Matti Davis
Original Assignee
Ayala Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ayala Pharmaceuticals Inc filed Critical Ayala Pharmaceuticals Inc
Publication of SG11202011041YA publication Critical patent/SG11202011041YA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Physiology (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SG11202011041YA 2018-05-06 2019-05-05 Combination compositions comprising bisfluoroalkyl-1,4- benzodiazepinone compounds and methods of use thereof SG11202011041YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862667540P 2018-05-06 2018-05-06
PCT/US2019/030771 WO2019217250A1 (en) 2018-05-06 2019-05-05 Combination compositions comprising bisfluoroalkyl-1,4- benzodiazepinone compounds and methods of use thereof

Publications (1)

Publication Number Publication Date
SG11202011041YA true SG11202011041YA (en) 2020-12-30

Family

ID=68468208

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202011041YA SG11202011041YA (en) 2018-05-06 2019-05-05 Combination compositions comprising bisfluoroalkyl-1,4- benzodiazepinone compounds and methods of use thereof

Country Status (12)

Country Link
US (2) US20210244745A1 (enExample)
EP (1) EP3790552A4 (enExample)
JP (1) JP7522661B2 (enExample)
KR (1) KR20210005714A (enExample)
CN (1) CN112218639A (enExample)
AU (2) AU2019266150A1 (enExample)
BR (1) BR112020022654A2 (enExample)
CA (1) CA3099479A1 (enExample)
IL (1) IL278492B2 (enExample)
MX (1) MX2020011826A (enExample)
SG (1) SG11202011041YA (enExample)
WO (1) WO2019217250A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210379079A1 (en) * 2018-05-06 2021-12-09 Ayala Pharmaceuticals Inc. Compositions comprising cd20 inhibitors and bisfluoroalkyl-1,4-benzodiazepinone compounds and methods of use thereof
US20220339162A1 (en) * 2018-05-06 2022-10-27 Ayala Pharmaceuticals Inc. Bisfluoroalkyl-1,4-benzodiazepinone compounds for treating desmoid tumors
EP3793564A4 (en) 2018-05-15 2022-03-30 Ayala Pharmaceuticals Inc. COMPOSITIONS CONTAINING BISFLUOROALKYL-L,4-BENZODIAZEPINONE COMPOUNDS FOR THE TREATMENT OF ADENOCARCINOMA
BR112020023975A2 (pt) * 2018-05-24 2021-02-23 Ayala Pharmaceuticals Inc. composições que compreendem os compostos de bisfluoroalquil-1,4-benzodiazepinona e imunoterapêuticos e métodos de uso das mesmas
JP2022533100A (ja) * 2019-05-15 2022-07-21 アヤラ ファーマシューティカルズ インコーポレイテッド Ｎｏｔｃｈ活性化乳がんを治療するためのビスフルオロアルキル－１，４－ベンゾジアゼピノン化合物
US20240299411A1 (en) * 2021-05-13 2024-09-12 Ayala Pharmaceuticals Inc. Compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds for treating cancer

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PA8852901A1 (es) * 2008-12-22 2010-07-27 Lilly Co Eli Inhibidores de proteina cinasa
TWI530489B (zh) * 2011-03-22 2016-04-21 必治妥美雅史谷比公司 雙（氟烷基）－１，４－苯二氮呯酮化合物
US20140357605A1 (en) * 2012-03-22 2014-12-04 Bristol-Myers Squibb Company Bis(fluoroalkyl)-1,4-benzodiazepinone compounds
AR087107A1 (es) * 2011-07-27 2014-02-12 Lilly Co Eli Compuesto inhibidor de la señalizacion de la trayectoria notch
EP2861255B1 (en) 2012-06-19 2019-10-09 The Broad Institute, Inc. Diagnostic and treatment methods in subjects having or at risk of developing resistance to cancer therapy
TWI614238B (zh) * 2012-09-21 2018-02-11 必治妥美雅史谷比公司 雙（氟烷基）－１，４－苯并二氮呯酮化合物及其前藥
JP2015531792A (ja) * 2012-09-21 2015-11-05 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ １，４−ベンゾジアゼピノン化合物のプロドラッグ
CN105101968A (zh) * 2013-04-04 2015-11-25 百时美施贵宝公司 治疗增殖性疾病的组合疗法
CN105793251B (zh) 2013-12-05 2018-10-12 豪夫迈·罗氏有限公司 具有亲电子官能性的杂芳基吡啶酮和氮杂-吡啶酮化合物
EP3212233B1 (en) * 2014-10-31 2020-06-24 Oncomed Pharmaceuticals, Inc. Combination therapy for treatment of disease
CN120661674A (zh) * 2016-03-15 2025-09-19 奥莱松基因组股份有限公司 用于治疗实体瘤的lsd1抑制剂的组合
MX380779B (es) 2016-04-12 2025-03-12 Lilly Co Eli Terapia combinatoria con inhibidores notch y cdk4/6
US20190185559A1 (en) * 2016-09-02 2019-06-20 The Brigham And Women's Hospital, Inc. Compositions and methods for treating neoplasias
IL268349B2 (en) * 2017-02-17 2024-08-01 Hutchinson Fred Cancer Res Combination therapies for treatment of bcma-related cancers and autoimmune disorders
EP3615055A1 (en) * 2017-04-28 2020-03-04 Novartis AG Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
EP3615068A1 (en) * 2017-04-28 2020-03-04 Novartis AG Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
US11970542B2 (en) * 2017-11-08 2024-04-30 Fred Hutchinson Cancer Center Bispecific antibodies specific for treating hematological malignancies

Also Published As

Publication number Publication date
JP2021523169A (ja) 2021-09-02
KR20210005714A (ko) 2021-01-14
AU2019266150A1 (en) 2021-01-07
JP7522661B2 (ja) 2024-07-25
US20210244745A1 (en) 2021-08-12
EP3790552A4 (en) 2022-06-15
IL278492B2 (en) 2025-03-01
CN112218639A (zh) 2021-01-12
US20210040050A1 (en) 2021-02-11
WO2019217250A1 (en) 2019-11-14
US12281085B2 (en) 2025-04-22
EP3790552A1 (en) 2021-03-17
IL278492B1 (en) 2024-11-01
IL278492A (enExample) 2021-01-31
MX2020011826A (es) 2021-01-15
AU2025201674A1 (en) 2025-03-27
CA3099479A1 (en) 2019-11-14
BR112020022654A2 (pt) 2021-03-09

Similar Documents

Publication Publication Date Title
ZA202007838B (en) Polymerases, compositions, and methods of use
ZA202007839B (en) Polymerases, compositions, and methods of use
IL277079A (en) Cartirin preparations and methods of use
IL280963A (en) Anti-5gdf1 antibodies, compounds and methods of use
IL278829A (en) The compositions containing bis-(fluoroalkyl)-1,4 benzodiazepines and immunotherapeutic substances and methods of using them
IL274276A (en) CASZ preparations and methods of use
GB2582100B (en) CAS12C Compositions and methods of use
PL3668937T3 (pl) Kompozycje i zastosowania Z-1-chloro-2,3,3,3-tetrafluoroprop-1-enu
IL288278A (en) Alternative 1-oxo-isoindolin-5-carboxamide compounds, compounds thereof, and methods of treatment therewith
HUE062446T2 (hu) Vegyületek, készítmények és eljárások
HUE065438T2 (hu) Vegyületek, készítmények és alkalmazási eljárások
ZA201906169B (en) Synthekine compositions and methods of use
SG11202105730TA (en) Benzamides of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof
IL276135A (en) Preparations and methods of use
ZA202100780B (en) Bismuth-thiol compositions and methods of use
SG11202011227VA (en) Compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds and methods of use thereof
IL277786A (en) AAV preparations, methods of preparation and methods of use
IL270505B1 (en) Compounds, preparations and methods
ZA202104192B (en) Mmpl3 inhibitors, compositions and uses thereof
HK40042751A (en) Combination compositions comprising bisfluoroalkyl-1,4- benzodiazepinone compounds and methods of use thereof
HK40042752A (en) Compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds and methods of use thereof
HK40062036A (en) Mixtures and compositions comprising 5-fluoro-4-imino-3- methyl-1-tosyl-3,4-dihydropyrimidin-2-one, and methods of use thereof
HK40072378A (en) Compounds, compositions, and methods of use
GB201808668D0 (en) Compounds and compositions and uses thereof
IL257226A (en) Compounds characterized by an inverse freezing property and their uses